RESULTS	The event-free survival at three years for the nonrandomized intensive-chemotherapy group was 39 + / - 5.1 percent , and for a contemporaneous group of patients each of whom received a histocompatible bone marrow transplant from a sibling , it was 52 + / - 8.0 percent .\